Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (Ad5-nCoV-IH) in Adults Aged 18 Years and Above Who Have Received One Dose of Intramuscular Ad5-nCoV
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SeiHOPE
- Sponsors Tianjin CanSino Biotechnology
- 14 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Nov 2021 New trial record